AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02319239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic fractionation
Description: During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
Study NCT03219112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation using X-box One & Kinect
Description: the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
Study NCT03652051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 High Dose
Description: AZR-MD-001 is an ophthalmic ointment
Study NCT03652051 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: AZR-MD-001 Vehicle
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Study NCT00615550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: 8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
Study NCT00615550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
Study NCT00982787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botanical extract from Passiflora incarnata
Description: Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period
Study NCT02088996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: longwave diathermy on high power and interferential therapy
Study NCT02088996 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: longwave diathermy on low power
Study NCT01870843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
Study NCT03174886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AADvac1 40 µg
Description: Active immunotherapy against neurofibrillary pathology.
Study NCT03174886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AADvac1 160 µg
Description: Active immunotherapy against neurofibrillary pathology.
Study NCT04463641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the Axone 4LV Lead
Description: Implantation of the Axone 4LV Lead
Study NCT04876508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accupressure
Description: Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
Study NCT04781764 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: surgery
Study NCT02526134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)
Study NCT02396641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care Checklist
Study NCT00697749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection
Study NCT00697749 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT02012829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GPs communication skills and CRC screening
Description: GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
Study NCT03691805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
Study NCT03691805 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
Study NCT02137629 — intervention group
Intervention type: DRUG
Intervention: Vidaza®
Description: The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
Study NCT00554866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample and buccal swab sample
Description: one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab.
Study NCT00966316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin，chinese herbs；
Description: aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
Study NCT03021187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
Study NCT03021187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
Study NCT04317053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAY
Description: Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
Study NCT01474148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS-8 (8-Channel implanted stimulator-telemeter)
Description: Surgical implantation of the 8-channel neuroprosthesis
Study NCT03021187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
Study NCT03021187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
Study NCT03388580 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoalveolar lavage (BAL)
Description: clinically indicated, elective BAL
Study NCT04137770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack and ketorolac
Description: Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
Study NCT00982787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botanical extract from Passiflora incarnata
Description: Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period
Study NCT02936076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Study NCT02936076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Delayed exercise intervention
Study NCT05221476 — intervention group
Intervention type: OTHER
Intervention: retrospective
Description: The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
Study NCT00023452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT + INH once weekly for 3 months given by DOT
Description: Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons > 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if > 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT).
Study NCT00023452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (INH) daily for 9 months
Description: Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
Study NCT03738150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept injection
Study NCT03738150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Study NCT04712318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Relex Smile
Description: Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
Study NCT04712318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Relex smile with fresh corneal lenticule implantation
Description: VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values.
Study NCT02540382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: covered stent
Description: A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions\* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
Study NCT02540382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: bare stent
Description: A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions.
Study NCT00949637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scouting Nutrition and Activity Program
Description: Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
Study NCT00949637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-care attentional control
Description: Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
Study NCT03858751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule before bedtime
Study NCT02693444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02693444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03858751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AZ
Description: LTM1201AZ oral capsule before sleep
Study NCT04620863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: t-DCS group
Description: All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
Study NCT02791048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired.
Study NCT00105027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: CRVO: observation; BRVO: standard care
Study NCT00105027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal triamcinolone injection
Description: 1 mg dose
Study NCT04620863 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
Study NCT00105027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal triamcinolone injection
Description: 4 mg
Study NCT00472667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procalcitonin guided strategy
Description: Procalcitonin guided strategy
Study NCT02886845 — intervention group
Intervention type: GENETIC
Intervention: rs183489969,rs185670819
Description: compare the frequency of two germline mutations in breast cancers and controls
Study NCT01478789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WD-PS intervention phase
Description: 2g/d of free plant sterol in 100g yogurt
Study NCT01478789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS-Ester intervention phase
Description: 2g/d of free plant sterol in 100g yogurt
Study NCT01478789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100g/d yogurt with no added plant sterol
Study NCT00887172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jing Fang Bai Du san
Description: The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Study NCT00887172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
Study NCT00887172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ying Qiao san
Description: The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Study NCT02678546 — intervention group
Intervention type: OTHER
Intervention: Other
Description: case review of diagnosed disease
Study NCT03858751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AT
Description: LTM1201AT oral capsule before sleep
Study NCT03858751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AG
Description: LTM1201AG oral capsule before sleep
Study NCT02316145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Habilitation (Internet-based support and coaching)
Description: Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
Study NCT03858751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AD
Description: LTM1201AD oral capsule before sleep
Study NCT03407352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Video Game Play
Description: 60 minutes of active video game play at a moderate intensity
Study NCT03407352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Video Game Play
Description: 60 minutes of passive video game play
Study NCT00875953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard neck dissection
Description: standard surgical technique
Study NCT00875953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel Dissection
Description: harmonic scalpel used for neck dissection after flaps are raised.
Study NCT03832946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB0139
Description: GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
Study NCT03832946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as inhalation once a day
Study NCT00724971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (CMC-544)
Description: 1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
Study NCT00724971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Rituxan)
Description: 375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.